Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Projected For Strong Expansion Through 2030: Key Trends And Future Outlook
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Value Growth And Long-Term Outlook
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has demonstrated significant expansion in recent years. It is anticipated to increase from $6.11 billion in 2025 to $6.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.1%. This historical development can be attributed to the rising occurrence of chronic pancreatitis, heightened awareness surrounding digestive ailments, constrained access to specialized diagnostic methods, the adoption of nutritional supplements, and the expansion of home healthcare offerings.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is set to experience substantial expansion in the upcoming years. It is forecast to grow to $8.97 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.2%. This projected increase is attributed to several factors, including advancements in personalized enzyme therapies, the integration of artificial intelligence in diagnostics, a growing need for non-invasive imaging techniques, the expansion of telehealth services, and an increasing focus on patient-centric nutritional management. Notable trends for the forecast period encompass advanced pancreatic enzyme replacement therapies, the development of point-of-care diagnostic solutions, personalized nutritional management programs, non-invasive imaging techniques specifically for EPI, and the wider integration of telehealth into EPI management.
Get A Free Sample Report With In-Depth Market Insights:
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Catalysts And Demand Drivers
The rising prevalence of diabetes is projected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market moving forward. Diabetes is defined as a long-term metabolic condition marked by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s insufficient insulin production or ineffective insulin utilization. Pancreatic enzyme replacement therapy (PERT), a component of EPI treatment, aids in enhancing nutrient absorption and can also improve glycemic control in individuals with both diabetes and EPI. As an illustration, in June 2024, data from The National Health Service (NHS England), a publicly funded UK healthcare system, revealed that the count of individuals identified with pre-diabetes in England climbed to 3,615,330 in 2023, representing an 18% increase from 3,065,825 in 2022. Furthermore, for those under 40, pre-diabetes cases saw a substantial increase of almost 25%, rising from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing population affected by diabetes is a key factor propelling the development of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Breakdown: Which Categories Lead On Revenue?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends Shaping Long-Term Demand
Key companies active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic alliance approach to boost technology integration and expand their market presence. A strategic partnership typically describes a collaborative relationship where two or more organizations combine their assets, expertise, and endeavors to achieve mutual goals. For example, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition company, announced the interim results from their Phase 1 clinical trial of CDX-7108, an experimental treatment designed for exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial lay the groundwork for further research that could significantly enhance treatment possibilities for patients living with EPI.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Leading Players And Competitive Positioning
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
View The Full Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
